Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aripiprazole (Abilify®) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G‐protein coupled receptors (GPCRs) [especially dopamine (D 2) and 5‐HT 1A] and antagonistic action at others (especially 5‐HT 2A). Clinical trials indicate that aripiprazole is effective in treating the positive and negative symptoms of schizophrenia. In short‐term studies rapid onset of action (within one week) has been demonstrated. Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder. At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and Schizoaffective disorder. There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population. In the long‐term studies, the use of aripiprazole was associated with continued efficacy, good compliance and increased time‐to‐relapse. Aripiprazole represents the first functionally selective atypical antipsychotic drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationKapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Cited by
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860
Structural insights into the lipid and ligand regulation of serotonin receptors
Xu, P., Huang, S., Zhang, H., Mao, C., Zhou, X. E., Cheng, X., Simon, I. A., Shen, D.-D., Yen, H.-Y., Robinson, C. V., et al. (2021) · Nature · doi:10.1038/s41586-021-03376-8 · Cited by 270
Azmitia, E. C., Singh, J. S., & Whitaker-Azmitia, P. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.002 · Cited by 107
Role of aripiprazole in treating mood disorders
García-Amador, M., Pacchiarotti, I., Valentí, M., Sanchez, R. F., Goikolea, J. M., & Vieta, E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.12.1777 · Cited by 25
Lai, J., Lu, Q., Zhang, P., Xu, T., Xu, Y., & Hu, S. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s122316 · Cited by 9
“9 Aripiprazole monotherapy, or as an adjuvant to mood stabilizers, is efficacious in managing acute mania and stabilization phases of BD, but not bipolar depression.”
Background
Metadata
- Authors
- Davies, M. A., Sheffler, D. J., & Roth, B. L.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 10
- Issue
- 4
- Pages
- 317-336
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W3023832413
- Cited by
- 156
- References
- 4
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. https://app.cochat.ai/papers/10.1111/j.1527-3458.2004.tb00030.x
- The paper
- Davies, M. A., Sheffler, D. J., & Roth, B. L. (2004). Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2004.tb00030.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.